28Oct2019Early Cancer Screening is Maturing. What Will It Mean for Drug Developers?/Stacy Lawrence/0/All, Cancer, Diagnostics28 Oct 2019Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.